A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

NCT05989724 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Colorectal Cancer

Interventions

DRUG: SON-DP

Sponsor

Qurgen Inc.